Adicet Bio gets FDA IND clearance for ADI-001 in lupus nephritis; plans Phase 1 in Q2 2024

Adicet Bio, Inc.

FDA cleared IND for ADI-001 in lupus nephritis Dec 2023; Phase 1 start planned Q2 2024.
Focusing ADI-001 Phase 1 GLEAN enrollment on MCL patients; June 2023 data showed 80% CR rate.
ADI-001 clinical update expected 2H 2024; evaluating accelerated approval pathway for MCL.
ADI-270 IND submission for renal cell carcinoma planned Q2 2024 after positive pre-IND meeting.
Cash and equivalents expected to fund operations into second half of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.